Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BioNTech Cell & Gene Therapies GmbH
Mainz, Rhineland-Palatinate, Germanybiontech.com ↗
- Ownership
- Private
- Employees
- ~5500
- Development stage
- Other
01
Overview
BioNTech’s mRNA vaccine (COMIRNATY, developed with Pfizer) was the first COVID-19 mRNA vaccine approved worldwide and is commercialized globally. In oncology, individualized and shared antigen mRNA vaccines, cell therapies, and antibody approaches are in multiple early and mid-stage trials, with positive Phase 1/2 data in personalized cancer immunotherapy and early signals in CAR-T for solid tumors.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- mRNA-based drugsCell therapyGene therapyProteinSmall moleculeMonoclonal antibodyBispecific monoclonal antibodyCAR-T cell therapyT cell receptor engineered T cell therapyVaccine
- Industry
- Pharma
02
Partnerships
Beyond the preview
Go deeper on BioNTech Cell & Gene Therapies GmbH.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioNTech Cell & Gene Therapies GmbH.